Gilead (GILD) director Bluestone trades 5,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Gilead Sciences director Jeffrey Bluestone reported an option exercise and share sale. On January 20, 2026, he exercised a non-qualified stock option for 5,000 shares of Gilead common stock at an exercise price of $67.45 per share, increasing his directly held common stock to 13,920 shares and leaving 4,665 option shares outstanding. On the same day, he sold 5,000 shares of common stock at a price of $123.50 per share, resulting in a remaining direct holding of 8,920 common shares. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025, and the option vests in 25% increments every three months starting May 12, 2021.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bluestone Jeffrey

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		M(1)		5,000	A	$67.45	13,920	D
Common Stock	01/20/2026		S(1)		5,000	D	$123.5	8,920	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)	$67.45	01/20/2026		M(1)			5,000	(2)	05/12/2031	Common Stock	5,000	$0	4,665	D

Explanation of Responses:

1. The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

2. 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Jeffrey A. Bluestone	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Gilead Sciences (GILD) director Jeffrey Bluestone report?

Jeffrey Bluestone reported exercising a non-qualified stock option for 5,000 shares of Gilead Sciences common stock at an exercise price of $67.45 per share, followed by a sale of 5,000 common shares at a price of $123.50 per share on January 20, 2026.

How many Gilead Sciences (GILD) shares does Jeffrey Bluestone hold after the reported Form 4 transactions?

After the reported transactions, Jeffrey Bluestone directly holds 8,920 shares of Gilead Sciences common stock and 4,665 non-qualified stock options.

Were Jeffrey Bluestone’s Gilead Sciences (GILD) trades under a Rule 10b5-1 plan?

Yes. The filing states that the transactions reported on this Form 4 were made under a Rule 10b5-1 trading plan adopted on February 13, 2025.

What is the vesting schedule of Jeffrey Bluestone’s Gilead Sciences stock option reported on this Form 4?

The option vests 25% on each three-month anniversary from May 12, 2021, so that it becomes fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting.

What role does Jeffrey Bluestone have at Gilead Sciences (GILD)?

Jeffrey Bluestone is identified in the filing as a director of Gilead Sciences, Inc.

What type of derivative security did Jeffrey Bluestone exercise in Gilead Sciences (GILD)?

He exercised a non-qualified stock option (right to buy) covering 5,000 shares of Gilead Sciences common stock at an exercise price of $67.45 per share, with the option expiring on May 12, 2031.